This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Dynamic Neutrophil-to-Lymphocyte Ratio: A Novel Prognosis Measure for Triple-Negative Breast Cancer.
Annals of surgical oncology · 2020
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.
Nature communications · 2017
Knowledge-Based Strategy to Improve Ligand Pose Prediction Accuracy for Lead Optimization.
Journal of chemical information and modeling · 2015
Latest funding
- $826,200
Bioresponsive Immunomodulator Nanocomplex for Selective Immunoengineering to Treat Lymph Node Metastasis
CIHR · 2024 · Co-investigator
- $105,000
Identification of biomarkers using single cell technology that inform on targeted and immune therapy treatment in melanoma
CIHR · 2023 · Supervisor
- $1,002,150
Engineering bacteria-based nanoplexes for melanoma immunomodulation
CIHR · 2023 · Co-investigator
3 publications.
Dynamic Neutrophil-to-Lymphocyte Ratio: A Novel Prognosis Measure for Triple-Negative Breast Cancer.
Moldoveanu D, Pravongviengkham V, Best G, Martínez C, Hijal T, Meguerditchian AN, Lajoie M, Dumitra S, Watson I, Meterissian S
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.
Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, Maurer M, Hafner C, Mayerhöfer M, Karanikas G, Jalili A, Bauer-Pohl V, Weihsengruber F, Rappersberger K, Koller J, Lang R, Hudgens C, Chen G, Tetzlaff M, Wu L, Frederick DT, Scolyer RA, Long GV, Damle M, Ellingsworth C, Grinman L, Choi H, Gavin BJ, Dunagin M, Raj A, Scholler N, Gross L, Beqiri M, Bennett K, Watson I, Schaider H, Davies MA, Wargo J, Czerniecki BJ, Schuchter L, Herlyn D, Flaherty K, Herlyn M, Wagner SN
Knowledge-Based Strategy to Improve Ligand Pose Prediction Accuracy for Lead Optimization.
Gao C, Thorsteinson N, Watson I, Wang J, Vieth M
Bioresponsive Immunomodulator Nanocomplex for Selective Immunoengineering to Treat Lymph Node Metastasis
Principal investigators: Chen, Guojun
Keywords: Cancer Immunotherapy; Drug Delivery; Immunoengineering; Lymph Node Metastasis; Nanomedicine; Nanotechnolgy
Identification of biomarkers using single cell technology that inform on targeted and immune therapy treatment in melanoma
Principal investigators: Magrill, Jamie A
Keywords: Cancer; Imaging Mass Cytometry; Immunology; Immunotherapy; Melanoma; Targeted Therapy; Tumor Immune Microenvironment
Engineering bacteria-based nanoplexes for melanoma immunomodulation
Principal investigators: Tabrizian, Maryam; Radzioch, Danuta
Keywords: 6-Bromo-Indirubin-3'-Oxime (6bio); Advanced Melanoma; Bacterial Colonization And Biodistribution; Characterization Of The Nanoplex And Carrier Systems; Copper Diethyldithiocarbamate (Cuet); Engineered Msr-1bacteria-Lpn Carrier; Immunotherapy; In-Vitro Immunomodulatory Effect Using Melanoma Cell Lines; Investigation Of Immune Response In Relevant Mouse Models; Lipid-Polymer Cuet/6bio Nanoplexes (Lnp)
Identification of biomarkers using single cell technology that inform on targeted and immune therapy treatment in melanoma
Principal investigators: Magrill, Jamie A
Keywords: Cancer; Imaging Mass Cytometry; Immunology; Immunotherapy; Melanoma; Targeted Therapy; Tumor Immune Microenvironment
Identification of biomarkers using single cell technology that inform on optimal duration of immunotherapy treatment in melanoma
Principal investigators: Watson, Ian R; Baetz, Tara; Dancey, Janet E; Song, Xinni
Keywords: Image Mass Cytometry; Immune Checkpoint Inhibitors; Immunotherapy; Melanoma Tumor Microenvironment; Single Cell Epigenetic Profiling; Single Cell Sequencing; Single Cell Technology
Defining the distinct roles of MAPK pathway mutations in immune and targeted therapy response in melanoma
Principal investigators: Watson, Ian R
Keywords: Braf; Cell Signalling; Cutaneous Melanoma; Immune Checkpoint Inhibitors; Mapk Pathway; Mouse Models Of Cancer; Nf1; Nras; Pd-L1; Targeted Therapy
Identifying Therapeutic Strategies to Target RAC1 P29S in Melanoma
Principal investigators: Heney, Kayla
Keywords: Cellular Migration; Crispr Screens; Cytoskeletal Reorganization; Iqgap1 Signalling; Metastatic Melanoma; Mouse Models; Proteolysis Targeting Chimera (Protac); Rac1 Signalling; Targeted Cancer Therapy; Ubiquitin Proteosome System
Investigation of the sexual dimorphic role of DDX3X in melanoma
Principal investigators: Watson, Ian R
Keywords: Cell Signalling; Cutaneous Melanoma; Cytof Image Mass Cytometry (Imc); Focused Proteomics; Genetics; Mouse Models Of Cancer; Oncogenes; Rna Helicase Ddx3x; Sex-Bias In Cancer; Tumor Suppressor
Canada Research Chair - Tier 2
Principal investigators: Watson, Ian R
Keywords: Crc
Integrative Analysis of Gene Expression Patterns in Cutaneous Melanoma
Principal investigators: Alkallas, Rached
Keywords: Deconvolution Of Tumor Composition; Genomics; Melanoma; Somatic Driver Mutations; Transcriptomics
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.